Who is sponsoring NCT03384511?

NCT03384511 is sponsored by Shandong Cancer Hospital and Institute.

What condition does NCT03384511 study?

NCT03384511 studies Malignancies, Stomach Cancer, Non-small Cell Lung Cancer, Esophageal Cancer, Breast Cancer, Ovary Cancer, Cervical Cancer.

What is the status of NCT03384511?

NCT03384511 is currently COMPLETED.

Last reviewed 2018-02-20 · How we verify

The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies.

NCT03384511 PHASE4 COMPLETED

This is an open-label, single arm study to explore whether 18F-ALF-NOTA-PRGD2 PET/CT scan can predict the efficacy and adverse events of apatinib in patients with malignancies. Integrin αvβ3 has been shown to play an important role in angiogenesis and up-regulated obviously in various types of tumor cells and activated endothelial cells. The arginine-glycine-aspartic acid (RGD) tripeptide sequence can bind to integrin αvβ3 with high affinity and specificity. The 18F-ALF-NOTA-PRGD2 will highly combine with αvβ3, and thus will monitor the antiangiogenic status.In the current study, investigators propose to evaluate the feasibility of 18F-RGD PET/CT in monitoring efficacy and adverse events of apatinib in malignancies.

Details

Lead sponsor	Shandong Cancer Hospital and Institute
Phase	PHASE4
Status	COMPLETED
Enrolment	38
Start date	Fri Sep 30 2016 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Sun Jan 28 2018 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

Malignancies
Stomach Cancer
Non-small Cell Lung Cancer
Esophageal Cancer
Breast Cancer
Ovary Cancer
Cervical Cancer

Interventions

Apatinib

Countries

China